Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

New Genetic Links to Colorectal Cancer Identified

January 3, 2013
By Anna Azvolinsky
Article

Using a large genome-wide study of more than 28,000 individuals, three new genetic links to colorectal cancer have been identified, holding the potential for new therapeutic targets.

Three new genetic links to colorectal cancer have been identified using a large genome-wide study of more than 28,000 individuals. The three new variants may hold potential new therapeutic targets and are helping researchers better understand the biology of colorectal cancer as well as the differential genetic basis of colorectal cancer in European and Asian populations. The study is published in Nature Genetics.

Researchers at the Vanderbilt-Ingram Cancer Center in Nashville, and colleagues in China, South Korea, and Japan analyzed 5,252 colorectal cancer cases and 9,071 control samples from the Asia Colorectal Cancer Consortium (ACCC) to identify novel colorectal cancer risk factors. The samples studied came from China, Japan, and Korea. The results were compared to the known genetic variants identified from European population results.

“This kind of work would not be possible without the support of investigators from multiple centers,” said Wei Zheng, MD, PhD, an Ingram professor of cancer research and lead author of the study.

The top four genetic loci were compared to two previous data sets-the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry (CCFR). Three of these were within the previous data sets but there were not enough data for strong associations. The current study has found the “needles in a haystack,” said Zheng, by rigorously testing the results to identify true associations using the genome-wide association study data that can identify more than 25,000 variants, many of which are false positives.

“A lot of work has been done in European descendants,” said Zheng. “Our study is the first one conducted in multiple East Asian populations. Looking at different ethnic groups is important because the genetic structures can be different enough that variants identified in one population do not explain risk in other populations Sometimes-it is much easier to identify some genetic variants in East Asian populations than European descendants.”

One of the loci is in close proximity to the CCND2 gene, a cyclin that has a critical role in cell cycle progression and has been shown to be overexpressed in colorectal tumors in various studies including The Cancer Genome Atlas (TCGA). Another variant is located proximal to the PITXI gene, a tumor suppressor gene that may activate TP53 and regulate the activity of the enzyme telomerase, which adds telomeres to the ends of chromosomes. A third genetic variant includes two genes-HAO1, which encodes a hydroxyacid oxidase; and PLCB1, which encodes phospholipase C-β1. PLCB1 has been previously shown to be overexpressed in colorectal cancer tissue.

Further genetic analyses of colorectal cancer continue to be necessary. Previous genome-wide studies have isolated 15 common genetic susceptibility loci in colorectal cancer but only 15% of heritable colorectal cancer is explained by these loci. All but one of these colorectal cancer studies analyzed samples from European populations even though genetic variants from non-European populations differ from those of other populations, including Asian populations.

Moreover, only 6% of colorectal cancer cases are explained by the genetic variants previously identified and associated with a high risk of the disease.

In addition to its work on colorectal cancer, the team is working on breast cancer genetics to identify additional genetic loci that confer risk of developing cancer, leading a consortium that has identified multiple susceptibility loci for breast cancer in Asians. “Interestingly,” said Zheng, “these loci were not discovered in previous studies conducted in European descendants, even with a very large sample size.”

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content
Advertisement

A total of 34 patients were included in the efficacy analysis; all received 320 mg of atebimetinib once daily plus 1000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel.

Atebimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC

Tim Cortese
September 25th 2025
Article

Atebimetinib with gemcitabine and nab-paclitaxel achieved a 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


analysis of biomarkers associated with outcomes from the trial was presented.3 The biomarker analysis demonstrated that intratumoral myeloid cells and T cells were activated in responding patients.

Mitazalimab/Chemo Yields Promising Survival/Responses in Untreated PDAC

Tim Cortese
September 22nd 2025
Article

At 30 months, mitazalimab plus mFOLFIRINOX achieved an OS rate of 21% in patients with previously untreated metastatic PDAC.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Favorable survival outcomes were identified, overall, in the wild-type and GOF groups vs the non-GOF group.

P53 Mutations May Reveal Viability of Different Pancreatic Cancer Therapies

Tim Cortese
September 20th 2025
Article

Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type or GOF mutations.


An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors

Roman Fabbricatore
September 18th 2025
Article

An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

Related Content
Advertisement

A total of 34 patients were included in the efficacy analysis; all received 320 mg of atebimetinib once daily plus 1000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel.

Atebimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC

Tim Cortese
September 25th 2025
Article

Atebimetinib with gemcitabine and nab-paclitaxel achieved a 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


analysis of biomarkers associated with outcomes from the trial was presented.3 The biomarker analysis demonstrated that intratumoral myeloid cells and T cells were activated in responding patients.

Mitazalimab/Chemo Yields Promising Survival/Responses in Untreated PDAC

Tim Cortese
September 22nd 2025
Article

At 30 months, mitazalimab plus mFOLFIRINOX achieved an OS rate of 21% in patients with previously untreated metastatic PDAC.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Favorable survival outcomes were identified, overall, in the wild-type and GOF groups vs the non-GOF group.

P53 Mutations May Reveal Viability of Different Pancreatic Cancer Therapies

Tim Cortese
September 20th 2025
Article

Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type or GOF mutations.


An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors

Roman Fabbricatore
September 18th 2025
Article

An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.